• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Ortho Clinical Diagnostics Holdings plc

    2/11/22 4:22:57 PM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $OCDX alert in real time by email
    SC 13G 1 d313057dsc13g.htm SC 13G SC 13G

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.     )*

     

     

    Ortho Clinical Diagnostics Holdings plc

    (Name of Issuer)

    Ordinary Shares

    (Title of Class of Securities)

    G6829J107

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. G6829J107   Schedule 13G   Page 1 of 15

     

      1   

    Names of Reporting Persons

     

    The Carlyle Group Inc.

      2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

      3  

    SEC Use Only

     

      4  

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person

    With

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    118,106,000

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    118,106,000

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    118,106,000

    10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11  

    Percent of Class Represented by Amount in Row 9

     

    49.9%

    12  

    Type of Reporting Person

     

    CO

     


    CUSIP No. G6829J107   Schedule 13G   Page 2 of 15

     

      1   

    Names of Reporting Persons

     

    Carlyle Holdings II GP L.L.C.

      2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

      3  

    SEC Use Only

     

      4  

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person

    With

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    118,106,000

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    118,106,000

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    118,106,000

    10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11  

    Percent of Class Represented by Amount in Row 9

     

    49.9%

    12  

    Type of Reporting Person

     

    OO (Limited Liability Company)

     


    CUSIP No. G6829J107   Schedule 13G   Page 3 of 15

     

      1   

    Names of Reporting Persons

     

    Carlyle Holdings II L.L.C.

      2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

      3  

    SEC Use Only

     

      4  

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person

    With

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    118,106,000

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    118,106,000

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    118,106,000

    10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11  

    Percent of Class Represented by Amount in Row 9

     

    49.9%

    12  

    Type of Reporting Person

     

    OO (Limited Liability Company)

     


    CUSIP No. G6829J107   Schedule 13G   Page 4 of 15

     

      1   

    Names of Reporting Persons

     

    CG Subsidiary Holdings L.L.C.

      2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

      3  

    SEC Use Only

     

      4  

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person

    With

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    118,106,000

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    118,106,000

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    118,106,000

    10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11  

    Percent of Class Represented by Amount in Row 9

     

    49.9%

    12  

    Type of Reporting Person

     

    OO (Limited Liability Company)

     


    CUSIP No. G6829J107   Schedule 13G   Page 5 of 15

     

      1   

    Names of Reporting Persons

     

    TC Group Cayman Investment Holdings, L.P.

      2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

      3  

    SEC Use Only

     

      4  

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares Beneficially Owned by Each Reporting Person

    With

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    118,106,000

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    118,106,000

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    118,106,000

    10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11  

    Percent of Class Represented by Amount in Row 9

     

    49.9%

    12  

    Type of Reporting Person

     

    PN

     


    CUSIP No. G6829J107   Schedule 13G   Page 6 of 15

     

      1   

    Names of Reporting Persons

     

    TC Group Cayman Investment Holdings Sub L.P.

      2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

      3  

    SEC Use Only

     

      4  

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares Beneficially Owned by Each Reporting Person

    With

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    118,106,000

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    118,106,000

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    118,106,000

    10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11  

    Percent of Class Represented by Amount in Row 9

     

    49.9%

    12  

    Type of Reporting Person

     

    PN

     


    CUSIP No. G6829J107   Schedule 13G   Page 7 of 15

     

      1   

    Names of Reporting Persons

     

    TC Group VI Cayman, L.L.C.

      2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

      3  

    SEC Use Only

     

      4  

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person

    With

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    118,106,000

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    118,106,000

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    118,106,000

    10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11  

    Percent of Class Represented by Amount in Row 9

     

    49.9%

    12  

    Type of Reporting Person

     

    OO (Limited Liability Company)

     


    CUSIP No. G6829J107   Schedule 13G   Page 8 of 15

     

      1   

    Names of Reporting Persons

     

    TC Group VI Cayman, L.P.

      2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

      3  

    SEC Use Only

     

      4  

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares Beneficially Owned by Each Reporting Person

    With

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    118,106,000

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    118,106,000

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    118,106,000

    10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11  

    Percent of Class Represented by Amount in Row 9

     

    49.9%

    12  

    Type of Reporting Person

     

    PN

     


    CUSIP No. G6829J107   Schedule 13G   Page 9 of 15

     

      1   

    Names of Reporting Persons

     

    Carlyle Partners VI Cayman Holdings, L.P.

      2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

      3  

    SEC Use Only

     

      4  

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares Beneficially Owned by Each Reporting Person

    With

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    118,106,000

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    118,106,000

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    118,106,000

    10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11  

    Percent of Class Represented by Amount in Row 9

     

    49.9%

    12  

    Type of Reporting Person

     

    PN

     


    CUSIP No. G6829J107   Schedule 13G   Page 10 of 15

     

    ITEM 1.

    (a)   Name of Issuer:

    Ortho Clinical Diagnostics Holdings plc (the “Issuer”).

     

      

    (b)   Address of Issuer’s Principal Executive Offices:

    1001 Route 202 Raritan, New Jersey 08869

     

    ITEM 2.

    (a)   Name of Person Filing:

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

    The Carlyle Group Inc.

    Carlyle Holdings II GP L.L.C.

    Carlyle Holdings II L.L.C.

    CG Subsidiary Holdings L.L.C.

    TC Group Cayman Investment Holdings, L.P.

    TC Group Cayman Investment Holdings Sub L.P.

    TC Group VI Cayman, L.L.C.

    TC Group VI Cayman, L.P.

    Carlyle Partners VI Cayman Holdings, L.P.

     

      

    (b)   Address or Principal Business Office:

    The principal business address of each of TC Group Cayman Investment Holdings, L.P., TC Group Cayman Investment Holdings Sub L.P., TC Group VI Cayman, L.P. and Carlyle Partners VI Cayman Holdings, L.P. is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001. The principal business address of each of each of the other reporting persons is c/o The Carlyle Group, 1001 Pennsylvania Ave., NW, Suite 220, Washington, DC 20004-2505.

     

      

    (c)   Citizenship of each Reporting Person is:

    Each of TC Group Cayman Investment Holdings, L.P., TC Group Cayman Investment Holdings Sub L.P., TC Group VI Cayman, L.P. and Carlyle Partners VI Cayman Holdings, L.P. is organized under the laws of the Cayman Islands. Each of the other Reporting Persons is organized under the laws of the State of Delaware.

     

      

    (d)   Title of Class of Securities:

    Ordinary shares, $0.00001 par value (“Ordinary Shares”).


    CUSIP No. G6829J107   Schedule 13G   Page 11 of 15

     

      

    (e)   CUSIP Number:

    G6829J107

     

    ITEM 3.

    Not applicable.

     

    ITEM 4.

    Ownership.

     

      (a-c)

    The ownership information presented below represents beneficial ownership of Ordinary Shares as of December 31, 2021, based upon 236,889,470 ordinary shares outstanding as of October 29, 2021, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2021.

     

    Reporting Person    Amount
    beneficially
    owned
         Percent
    of class:
        Sole power to
    vote or to direct
    the vote:
         Shared power
    to vote or to
    direct the vote:
         Sole power to
    dispose or to
    direct the
    disposition of:
         Shared power
    to dispose or to
    direct the
    disposition of:
     

    The Carlyle Group Inc.

         118,106,000        49.9 %      0        118,106,000        0        118,106,000  

    Carlyle Holdings II GP L.L.C.

         118,106,000        49.9 %      0        118,106,000        0        118,106,000  

    Carlyle Holdings II L.L.C.

         118,106,000        49.9 %      0        118,106,000        0        118,106,000  

    CG Subsidiary Holdings L.L.C.

         118,106,000        49.9 %      0        118,106,000        0        118,106,000  

    TC Group Cayman Investment Holdings, L.P.

         118,106,000        49.9 %      0        118,106,000        0        118,106,000  

    TC Group Cayman Investment Holdings Sub L.P.

         118,106,000        49.9 %      0        118,106,000        0        118,106,000  

    TC Group VI Cayman, L.L.C.

         118,106,000        49.9 %      0        118,106,000        0        118,106,000  

    TC Group VI Cayman, L.P.

         118,106,000        49.9 %      0        118,106,000        0        118,106,000  

    Carlyle Partners VI Cayman Holdings, L.P.

         118,106,000        49.9 %      0        118,106,000        0        118,106,000  

    Reflects ordinary shares held of record by Carlyle Partners VI Cayman Holdings, L.P. The Carlyle Group Inc., a publicly traded company listed on Nasdaq, is the sole member of Carlyle Holdings II GP L.L.C., which is the managing member of Carlyle Holdings II L.L.C., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the general partner of TC Group Cayman Investment Holdings, L.P., which is the general partner of TC Group Cayman Investment Holdings Sub L.P., which is the sole member of TC Group VI Cayman, L.L.C., which is the general partner of TC Group VI Cayman, L.P., which is the general partner of Carlyle Partners VI Cayman Holdings, L.P. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Carlyle Partners VI Cayman Holdings, L.P. Each of them disclaims beneficial ownership of such securities.


    CUSIP No. G6829J107   Schedule 13G   Page 12 of 15

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    Not applicable.


    CUSIP No. G6829J107   Schedule 13G   Page 13 of 15

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 11, 2022

     

    The Carlyle Group Inc.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:   Chief Financial Officer

     

    Carlyle Holdings II GP L.L.C.
    By: The Carlyle Group Inc., its sole member
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:   Chief Financial Officer

     

    Carlyle Holdings II L.L.C.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:   Managing Director

     

    CG Subsidiary Holdings L.L.C.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:   Managing Director

     

    TC Group Cayman Investment Holdings, L.P.
    By: CG Subsidiary Holdings L.L.C., its general partner
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:   Managing Director


    CUSIP No. G6829J107   Schedule 13G   Page 14 of 15

     

    TC Group Cayman Investment Holdings Sub L.P.
    By: TC Group Cayman Investment Holdings, L.P., its general partner
    By: CG Subsidiary Holdings L.L.C., its general partner
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   Curtis L. Buser
    Title:   Managing Director

     

    TC Group VI Cayman, L.L.C.
    By:   /s/Jeremy W. Anderson
    Name:   Jeremy W. Anderson
    Title:   Authorized Person

     

    TC Group VI Cayman, L.P.
    By: TC Group VI Cayman, L.L.C., its general partner
    By:   /s/Jeremy W. Anderson
    Name:   Jeremy W. Anderson
    Title:   Authorized Person

     

    Carlyle Partners VI Cayman Holdings, L.P.
    By: TC Group VI Cayman, L.P., its general partner
    By: TC Group VI Cayman, L.L.C., its general partner
    By:   /s/Jeremy W. Anderson
    Name:   Jeremy W. Anderson
    Title:   Authorized Person


    CUSIP No. G6829J107   Schedule 13G   Page 15 of 15

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    24    Power of Attorney
    99    Joint Filing Agreement.
    Get the next $OCDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OCDX

    DatePrice TargetRatingAnalyst
    2/17/2022$21.00In-Line → Outperform
    Evercore ISI Group
    12/27/2021$24.68Buy → Neutral
    HC Wainwright & Co.
    12/27/2021$29.00 → $25.00Overweight → Equal-Weight
    Barclays
    12/23/2021Outperform → In-Line
    Evercore ISI Group
    10/4/2021$27.00Buy
    Citigroup
    8/5/2021$27.00 → $30.00Buy
    HC Wainwright & Co.
    8/5/2021$23.00Outperform
    Credit Suisse
    7/13/2021$24.00 → $27.00Overweight
    Barclays
    More analyst ratings

    $OCDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ortho Clinical Diagnostic upgraded by Evercore ISI Group with a new price target

    Evercore ISI Group upgraded Ortho Clinical Diagnostic from In-Line to Outperform and set a new price target of $21.00

    2/17/22 6:13:24 AM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Ortho Clinical Diagnostic downgraded by HC Wainwright & Co. with a new price target

    HC Wainwright & Co. downgraded Ortho Clinical Diagnostic from Buy to Neutral and set a new price target of $24.68

    12/27/21 6:03:32 AM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Ortho Clinical Diagnostic downgraded by Barclays with a new price target

    Barclays downgraded Ortho Clinical Diagnostic from Overweight to Equal-Weight and set a new price target of $25.00 from $29.00 previously

    12/27/21 5:11:13 AM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $OCDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quidel and Ortho Announce Expected Closing of Ortho Transaction

    SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Quidel Corporation (NASDAQ:QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc ("Ortho"), one of the world's larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022. On May 26, 2022, the High Court of Justice of England and Wales issued an order under Part 26 of the UK Companies Act sanctioning the scheme of arrangement to be undertaken by Ortho in connection with the business combinations (the "Ortho Scheme Order")

    5/26/22 12:24:44 PM ET
    $OCDX
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Quidel and Ortho Announce Expected Closing of Ortho Transaction

    Quidel Corporation (NASDAQ:QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc ("Ortho"), one of the world's larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022. On May 26, 2022, the High Court of Justice of England and Wales issued an order under Part 26 of the UK Companies Act sanctioning the scheme of arrangement to be undertaken by Ortho in connection with the business combinations (the "Ortho Scheme Order"). The order will become effective once the Or

    5/26/22 12:05:00 PM ET
    $OCDX
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Ortho Clinical Diagnostics Shareholders Approve Quidel Transaction

    RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) ("Ortho" or the "Company"), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation (NASDAQ:QDEL) ("Quidel") pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto (the "BCA"). The closing of the transactions contemplated by the BCA is subject to sanction of the combination by the High Court of Justice of England and W

    5/16/22 4:45:00 PM ET
    $OCDX
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $OCDX
    Financials

    Live finance-specific insights

    View All

    Ortho Clinical Diagnostics to Report First Quarter 2022 Results on May 4, 2022

    RARITAN, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close on Wednesday, May 4, 2022. Ortho Clinical Diagnostics will hold a conference call the same day at 4:30 pm ET to discuss the results. Interested parties can access the call and accompanying presentation on the "Investors" portion of the Company's website at https://ir.orthoclinicaldiagnostics.com/. Presentation materials will also be posted to the "Investors" portion of the website at the time of the call. Thos

    4/20/22 4:14:38 PM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2021 Results

    Highlights  • Fourth quarter Core revenue grew 3.5% to $518.9 million, or 4.3% in constant currency and 8.0% excluding CoV-2 assay sales  • Fiscal year Core revenue grew 16.1% to $2.01 billion, or 14.6% in constant currency and 15.7% excluding CoV-2 assay sales  • Fourth quarter Operating income was $31.1 million, while Adjusted EBITDA was $127.9 million  • Fiscal year Operating income was $173.9 million, while Adjusted EBITDA was $548.1 million, up 20.2% year-over-year RARITAN, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) (the "Company"), one of the world's largest pure-play in-vitro diagnostics (IVD) companies, today announced financial

    2/16/22 4:05:00 PM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Ortho Clinical Diagnostics Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2021

    Expects 4Q Reported and Constant Currency Core Revenue Growth of ~4%Fiscal Year Reported and Constant Currency Core Revenue Growth of ~16% and ~15%, respectively RARITAN, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) (the "Company"), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced preliminary unaudited revenue results for the fourth quarter and fiscal year ended January 2, 2022. The Company is providing these updates in advance of its presentation at the J.P. Morgan Healthcare Conference on January 11, 2022. Selected Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results (Unaudit

    1/6/22 4:50:52 PM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $OCDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Iskra Michael S. returned 150,000 units of Ordinary Shares to the company, closing all direct ownership in the company

    4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)

    6/1/22 4:16:06 PM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Busky Joseph M

    4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)

    6/1/22 4:15:59 PM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4: Schlesinger Michael A. returned 87,637 units of Ordinary Shares to the company, closing all direct ownership in the company

    4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)

    6/1/22 4:15:38 PM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $OCDX
    SEC Filings

    View All

    SEC Form 15-12B filed by Ortho Clinical Diagnostics Holdings plc

    15-12B - Ortho Clinical Diagnostics Holdings plc (0001828443) (Filer)

    6/6/22 4:03:53 PM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Ortho Clinical Diagnostics Holdings plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Ortho Clinical Diagnostics Holdings plc (0001828443) (Filer)

    5/27/22 9:11:58 AM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 25-NSE filed by Ortho Clinical Diagnostics Holdings plc

    25-NSE - Ortho Clinical Diagnostics Holdings plc (0001828443) (Subject)

    5/27/22 8:02:56 AM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $OCDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ortho Clinical Diagnostics Holdings plc

    SC 13G - Ortho Clinical Diagnostics Holdings plc (0001828443) (Subject)

    2/14/22 2:20:43 PM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Ortho Clinical Diagnostics Holdings plc

    SC 13G - Ortho Clinical Diagnostics Holdings plc (0001828443) (Subject)

    2/11/22 4:22:57 PM ET
    $OCDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care